Pharmaceutical company Moderna is developing a new vaccine for patients with heart attack and heart failure. In your last updatethe company announced this week that the first patients have already received the injection, called mRNA-0184, in a phase 1B clinical trial.
The application is made directly into the heart of patients weeks or months following suffering a heart attack, helping with their recovery.
More on the subject
-
Health
See what is the main symptom of heart attack in young women
-
Health
Eye exam may predict heart attack risk, study finds
-
Health
Heart attack: learn to identify signs that precede a heart attack
-
Health
Panic attack or heart attack? Learn to spot the difference
According to the pharmaceutical company, the vaccine uses messenger RNA (mRNA) technology, which carries genetic information that “teaches” cells to produce proteins or hormones.
During a heart attack, heart muscle cells can die without the possibility of being regenerated. In the case of the heart attack vaccine, the messenger mRNA injected into the heart encodes relaxin, a natural hormone known to improve blood flow, helping repair damaged heart muscle and grow new vessels.
All patients who received the vaccine in the clinical trial have stable heart failure and the trial will determine how safe the shot is, as well as whether it has side effects.
Get news from metropolises on your Telegram and stay on top of everything! Just access the channel: https://t.me/metropolesurgente.
window._taboola = window._taboola || [];
_taboola.push(
mode: “thumbnails-c-3×1”,
container: “taboola-mid-article”,
placement: “Mid Article”,
target_type: “mix”
);
The post Moderna tests vaccine for heart attack applied directly to the heart first appeared on Metropolis.
